title: Evaluation of antibodies to hepatitis C virus in a study of transfusion-associated hepatitis.
abstract: BACKGROUND
  The hepatitis C virus (HCV) is now known to be the chief cause of transfusion-associated non-A, non-B hepatitis, but the prevalence of HCV among blood donors and the frequency of transmission by blood transfusion are unknown.
  
  
  METHODS
  To assess the sensitivity and specificity of a test for antibody to HCV, we tested serum samples from participants in a large study of transfusion-associated hepatitis. Samples were obtained prospectively from consecutive adults undergoing open-heart surgery in Spain, but were tested retrospectively, after the antibody enzyme immunoassay for anti-HCV became available.
  
  
  RESULTS
  Of 280 transfusion recipients given a total of 1109 units of blood, 27 (9.6 percent) had transfusion-associated non-A, non-B hepatitis (mean follow-up, 52 weeks) and 24 of the 27 seroconverted to anti-HCV-positive, whereas only 2 (0.8 percent) of the remaining transfusion recipients seroconverted. Among the 1044 donor specimens available for testing, 16 (1.5 percent) had anti-HCV antibody. Only 1 additional seropositive donor was found when 44 implicated donors who had been seronegative were retested 9 to 12 months later. Of the 16 recipients of anti-HCV-positive blood, 14 (88 percent) had transfusion-associated hepatitis and seroconverted to anti-HCV-positive. The remaining two recipients had neither hepatitis nor anti-HCV antibody. Among 25 patients with non-A, non-B hepatitis for whom all transfused blood was tested, 14 had received blood positive for anti-HCV.
  
  
  CONCLUSIONS
  About 90 percent of blood donors with antibody to HCV have infectious virus in their blood. The screening of blood donors for anti-HCV antibody should prevent about half the cases of transfusion-associated hepatitis, but the donors with infectious virus who are anti-HCV-negative may remain seronegative for prolonged periods.
authors.affiliation: Department of Internal Medicine, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
authors.forename: J I
authors.initials: JI
authors.lastname: Esteban
authors.forename: A
authors.initials: A
authors.lastname: González
authors.forename: J M
authors.initials: JM
authors.lastname: Hernández
authors.forename: L
authors.initials: L
authors.lastname: Viladomiu
authors.forename: C
authors.initials: C
authors.lastname: Sánchez
authors.forename: J C
authors.initials: JC
authors.lastname: López-Talavera
authors.forename: D
authors.initials: D
authors.lastname: Lucea
authors.forename: C
authors.initials: C
authors.lastname: Martin-Vega
authors.forename: X
authors.initials: X
authors.lastname: Vidal
authors.forename: R
authors.initials: R
authors.lastname: Esteban
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001782:Blood Donors; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005500:Follow-Up Studies; D016174:Hepacivirus / Q000276:immunology*; D006508:Hepatitis Antibodies / Q000032:analysis* / Q000096:biosynthesis; D006526:Hepatitis C / Q000175:diagnosis / Q000209:etiology / Q000276:immunology*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D065227:Transfusion Reaction
chemical_list: D006508:Hepatitis Antibodies; D000410:Alanine Transaminase